Kopran Q1 FY2026-27: Revenue rises, margins soften as mix and forex swing

Revenue from operations was Rs 15,399 lakhs in Q1 FY 2026-27, and sales or other income was Rs 15,605 lakhs as shown in the financial snapshot.

EBITDA (excluding other income and forex losses) was Rs 1,588 lakhs and EBITDA margin was 10.31 percent in Q1 FY 2026-27.

Net profit was Rs 670 lakhs in Q1 FY 2026-27 on a consolidated basis.

For FY 2025-26, API export sales were Rs 14,598 lakhs and local sales were Rs 22,737 lakhs. For Q1 FY 2026-27, export sales were Rs 3,861 lakhs and local sales were Rs 5,677 lakhs.

FY 2025-26 formulations sales were across Africa, South Africa, Southeast Asia, UK, Middle East and North Africa, Canada, and Latem. Q1 FY 2026-27 shows Africa, South Africa, Southeast Asia, Canada, Latem, and Middle East and North Africa.

API facility is at MIDC Mahad, Maharashtra. Formulations facility is at Khopoli, Maharashtra.

Formulations are approved by 15 countries including MHRA UK, SAPHRA South Africa, MMA Malta EU GMP, and Health Canada. The API plant is approved by ANVISA and WHO GMP, and by US FDA and EU GMP except the sterile facility.